Benefits
Antioxidant protection
Alpha-tocopherol is the primary fat-soluble antioxidant in cell membranes, donating hydrogen atoms to lipid peroxyl radicals and terminating chain reactions that would otherwise destroy membrane integrity.
Immune modulation
Enhances T-cell proliferation and natural killer cell activity. Studies show supplementation improves immune response in elderly individuals, who typically exhibit lower vitamin E status.
LDL-oxidation mechanism (cardiovascular outcomes null)
Vitamin E reduces oxidation of LDL cholesterol in the lab — a mechanistic step in plaque formation — but this has not translated into clinical benefit. In large outcome trials, including the cited HOPE-TOO study (400 IU/day), vitamin E did not reduce cardiovascular events, and pooled analyses suggest possible harm at high doses. Any mechanistic effect on LDL oxidation should not be read as a cardiovascular benefit.
Skin health
Protects skin cell membranes from UV-induced oxidative damage. Best evidence here is topical; controlled data for oral vitamin E improving wound healing or reversing photoaging in people are limited and inconsistent.
Mechanism of action
Lipid peroxidation termination
Alpha-tocopherol donates a hydrogen atom to lipid peroxyl radicals (LOO•), converting them to lipid hydroperoxides and generating a tocopheroxyl radical, which is then regenerated by vitamin C. This interrupts the chain reaction of lipid peroxidation.
Gene expression regulation
Tocopherols modulate expression of genes involved in inflammation (NF-κB pathway), cellular adhesion, and immune cell differentiation independent of their antioxidant activity.
Platelet aggregation inhibition
Vitamin E inhibits platelet aggregation by reducing thromboxane synthesis and protein kinase C activity, contributing to its cardiovascular protective effects.
Clinical trials
Clinical trial of 400 IU/day vitamin E vs. placebo in 9,541 high-risk cardiovascular patients over 4.5 years.
9,541 adults with CVD or diabetes. 4.5-year follow-up.
No significant reduction in cardiovascular events or cancer. No benefit on primary endpoints (and vitamin E was associated with a higher rate of heart failure and heart-failure hospitalization). Highlighted limitations of alpha-tocopherol alone for CVD prevention.
Clinical trial of vitamin E supplementation (200 mg/day) vs. placebo in 88 adults over age 65 for 4 months.
88 elderly adults. 4-month intervention.
Significant improvement in delayed-type hypersensitivity response, antibody titers, and T-cell proliferation. Supports use in elderly populations.